Duality Biotherapeutics, Inc. (HKG:9606)
Hong Kong · Delayed Price · Currency is HKD 169.80
+1.20 (0.71%)
Oct 21, 2026, 3:59 PM HKT
Duality Biotherapeutics Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| 842.13 | 1,852 | 1,941 | 1,787 | 1.6 | |
Revenue Growth | -61.20% | -4.61% | 8.66% | 111558.75% | - |
Cost of Revenue | 1,076 | 1,263 | 1,157 | 427.66 | - |
Gross Profit | -233.67 | 589.09 | 784.67 | 1,359 | 1.6 |
Selling, General & Admin | 170.61 | 214.61 | 158.69 | 62.57 | 31.92 |
Research & Development | 1,095 | 837.77 | 815.38 | 559 | 339.89 |
Other Operating Expenses | -5.61 | -3.16 | -2.36 | 1.06 | -0.06 |
Operating Expenses | 1,260 | 1,049 | 971.71 | 622.62 | 371.75 |
Operating Income | -1,494 | -460.12 | -187.04 | 736.27 | -370.15 |
Interest Expense | -3.18 | -1.21 | -0.25 | -0.19 | -0.08 |
Interest & Investment Income | 111.74 | 99.31 | 48.11 | 34.48 | 3.27 |
Currency Exchange Gain (Loss) | -76.21 | -34.74 | 12.27 | 41.94 | 1.12 |
Other Non Operating Income (Expenses) | 13.73 | -2,206 | -873.42 | -1,018 | -21.7 |
EBT Excluding Unusual Items | -1,448 | -2,603 | -1,000 | -205.4 | -387.53 |
Asset Writedown | - | - | -21.35 | - | - |
Other Unusual Items | 9.13 | 7.99 | 7.12 | 3.15 | 0.44 |
Pretax Income | -1,439 | -2,595 | -1,015 | -202.25 | -387.09 |
Income Tax Expense | - | - | 35.89 | 155.26 | - |
Net Income | -1,439 | -2,595 | -1,050 | -357.51 | -387.09 |
Net Income to Common | -1,439 | -2,595 | -1,050 | -357.51 | -387.09 |
Net Income Growth | - | - | - | - | - |
Shares Outstanding (Basic) | 89 | 65 | 8 | 8 | 8 |
Shares Outstanding (Diluted) | 89 | 65 | 8 | 8 | 8 |
Shares Change | 259.84% | 714.45% | - | - | - |
EPS (Basic) | -16.09 | -39.82 | -131.30 | -44.69 | -48.39 |
EPS (Diluted) | -16.09 | -39.82 | -131.30 | -44.69 | -48.39 |
EPS Growth | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Free Cash Flow | -833.23 | 183.08 | 281.7 | 805.05 | -301.95 |
Free Cash Flow Per Share | -9.32 | 2.81 | 35.21 | 100.63 | -37.74 |
Gross Margin | -27.75% | 31.81% | 40.42% | 76.06% | 100.00% |
Operating Margin | -177.37% | -24.85% | -9.63% | 41.21% | -23134.25% |
Profit Margin | -170.82% | -140.13% | -54.11% | -20.01% | -24193.13% |
Free Cash Flow Margin | -98.94% | 9.89% | 14.51% | 45.06% | -18872.00% |
EBITDA | -1,485 | -452.7 | -182.46 | 737.75 | -369.92 |
EBITDA Margin | -176.29% | -24.45% | -9.40% | 41.30% | - |
D&A For EBITDA | 9.14 | 7.43 | 4.58 | 1.48 | 0.23 |
EBIT | -1,494 | -460.12 | -187.04 | 736.27 | -370.15 |
EBIT Margin | -177.37% | -24.85% | -9.63% | 41.21% | - |